首页> 外文期刊>Journal of pharmaceutical sciences. >In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole
【24h】

In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole

机译:不同粒径喷雾干燥的伊曲康唑的体外和体内性能

获取原文
获取原文并翻译 | 示例
           

摘要

The objectives of the present study were to formulate and optimize different sized liquid and solid nanocrystalline formulations and evaluate their in vitro and in vivo performance to determine the effect of particle size on the oral bioavailability of solid nanocrystalline formulations. Nanotechnology is a promising approach to solve the problem of poor oral bioavailability of Biopharmaceutical Classification System class II/IV compounds. However, the highly exposed surface area of nanocrystals and hence their high Gibb's free energy poses a great challenge to nanocrystalline suspension stabilization. In this study, stabilization was achieved by preparing spray-dried nanocrystalline powders. A design of experiment approach was utilized to optimize the nanocrystalline suspensions/powders. On the basis of drug solubility studies, polyvinylpyrrolidone 40 KDa and sodium lauryl sulfate were selected for wet milling processing. Mannitol was chosen as the auxiliary excipient for spray-drying processing. In vitro dissolution utilizing a United States Pharmacopeia (USP) apparatus II showed superior release profiles for both liquid and nanocrystalline powder formulations compared with coarse-sized and unmilled formulations. Significantly, the oral bioavailability of nanocrystalline formulations with particle size of 280 nm was more than 20 times that of the unmilled formulation, whereas the nanocrystalline formulation with particle size of 750 nm showed only a 2.8 times increase in bioavailability compared with the unmilled formulation. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3018-3028, 2015
机译:本研究的目的是配制和优化不同尺寸的液体和固体纳米晶制剂,并评估其体外和体内性能,以确定粒径对固体纳米晶制剂口服生物利用度的影响。纳米技术是解决生物药物分类系统II / IV类化合物口服生物利用度低的问题的有前途的方法。然而,纳米晶体的高度暴露的表面积以及因此其高的吉布自由能对纳米晶体悬浮液的稳定性提出了巨大的挑战。在这项研究中,通过制备喷雾干燥的纳米晶体粉末实现了稳定。实验方法的设计被用来优化纳米晶体悬浮液/粉末。在药物溶解度研究的基础上,选择了40 KDa的聚乙烯吡咯烷酮和十二烷基硫酸钠进行湿磨工艺。选择甘露醇作为喷雾干燥工艺的辅助赋形剂。与美国药典(USP)装置II进行的体外溶出相比,液体和纳米晶体粉末制剂的释放曲线均优于粗粉和未研磨的制剂。值得注意的是,粒径为280 nm的纳米晶体制剂的口服生物利用度是未研磨制剂的20倍以上,而粒径为750 nm的纳米晶体制剂的生物利用度仅比未研磨制剂高2.8倍。 (c)2014年Wiley Periodicals,Inc.和美国药剂师协会J Pharm Sci 104:3018-3028,2015

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号